Acquisition pumps up lab stock

FORT MYERS — Cancer-testing laboratory NeoGenomics posted 159% quarterly revenue growth, boosted by its recent acquisition of rival Clarient from GE Healthcare.

The stock of NeoGenomics jumped nearly 10% on the news. The company's shares are publicly traded on Nasdaq (symbol: NEO; recent price: $8.20).

The Fort Myers-based company reported net income of $155,000 on revenues of $59.7 in the quarter ending March 31. That compares with a net loss of $761,000 on revenues of $23 million in the same quarter one year ago.